Navigation Links
Wyeth Declares Preferred Stock Dividend
Date:11/20/2008

MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- At a meeting of the Board of Directors of Wyeth (NYSE: WYE), held today, a dividend of fifty cents($0.50) per share on the outstanding shares of Preferred Stock was declared payable on January 2, 2009 to stockholders of record at the close of business on December 12, 2008.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
2. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
3. Wyeth Announces Increase in Common Stock Dividend
4. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
5. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
6. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
7. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
8. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
9. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
10. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
11. Wyeth Declares Common and Preferred Stock Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Minn., July 20, 2017   KCNQ2 Cure ... genetic evaluations company, today announced that they have ... a genetic mutation implicated in KCNQ2 epileptic encephalopathy. ... for a second case involving an additional KCNQ2 ... Cure Alliance and Pairnomix entered into a collaboration ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, ... a leading science and technology company, has implemented Genedata Biologics ™ to ... areas of Oncology, Immunology, and Neurodegenerative Diseases. , The need to systematically evaluate ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... its drug delivery device testing capabilities to encompass the full series of ISO ... comprehensive evaluations of fittings for medical device and drug delivery systems. With this ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... Ph.D. , recently participated in the BiG (Biomedical Innovation Group) annual meeting in ... discussions of CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing highly personalized ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):